Investigating the role of ESRRB in glioblastoma treatment
Novel functions of ESRRB in glioblastoma
This study is looking at a new way to treat glioblastoma, a tough type of brain cancer, by using a special compound to target a specific protein that could help kill cancer cells and stop them from spreading, with the hope of improving survival for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11031341 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer, and explores how the manipulation of specific alternative splicing programs can lead to new treatment strategies. The study examines the estrogen-related receptor beta (ESRRB) and its beta2 isoform, which has been linked to improved survival in glioblastoma patients. By using a synthetic agonist to activate beta2, researchers aim to induce cell death in glioblastoma cells and reduce their ability to invade surrounding tissues. The ultimate goal is to develop novel therapeutic approaches that could improve outcomes for patients diagnosed with this deadly disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for glioblastoma patients.
How similar studies have performed: Previous research has shown promising results in targeting alternative splicing in cancer therapies, suggesting that this approach may hold significant potential.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Riggins, Rebecca B — Georgetown University
- Study coordinator: Riggins, Rebecca B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.